Atavistik Bio

About Atavistik Bio

Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics, with an internal focus on rare hematology. Atavistik Bio is advancing multiple programs with best-in-class potential, including the lead asset, ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management.